Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 55/100

Failure Rate

25.0%

1 terminated/withdrawn out of 4 trials

Success Rate

75.0%

-11.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

133%

4 of 3 completed trials have results

Key Signals

4 with results

Enrollment Performance

Analytics

N/A
4(100.0%)
4Total
N/A(4)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT04173247Not ApplicableCompleted

Study of KeraStat Cream for Radiation Dermatitis During Head and Neck Radiotherapy

Role: collaborator

NCT03564795Not ApplicableTerminated

Effectiveness of KeraStat Gel for Improved Cosmesis of Partial Thickness Burns

Role: lead

NCT04058054Not ApplicableCompleted

Skin Prick Test of KeraStat® Cream

Role: lead

NCT03559218Not ApplicableCompleted

KeraStat(R) Cream for Radiation Dermatitis

Role: lead

All 4 trials loaded